Results of Operations and Financial Condition. On August 6, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results and provided a business update for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by referen…

Chief Operating Officer, Chief Financial Officer — Alex Kelly, Naresh Tanna: The company promoted Alex Kelly to Chief Operating Officer and appointed Naresh Tanna as the new Chief Financial Officer, reflecting significant internal leadership changes.

by reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements This C…

Other Events In its updated corporate deck and as previously reported, the Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. The Company is targeting year-end 2026 for the next program update. Also in its updated corporate deck, the Company announced activation…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. The information set forth in

Entry into a Material Definitive Agreement. On June 10, 2026, Precision BioSciences, Inc. (the “Company”) and Banc of California (the “Lender”) entered into a First Amendment to Amended and Restated Loan and Security Agreement (the “First Amendment”).. The First Amendment amended the Amended and Restated Loan and Security Agreement, dated July 31, 2024, between the Company and Lender (as amended, including the First Amendment, the “Loan and Security Agreement”). The First Amendment extended t…

Other Events On May 27, 2026, the Company issued a press release to announce new and late-breaking PBGENE-HBV clinical data from the ELIMINATE-B study at EASL. Clinical highlights from the press release include: • New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. • In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out po…

The filing pertains to the amendment and restatement of a compensatory plan, not a management change.

Results of Operations and Financial Condition. On May 5, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by reference into, this Item 2.02 (includin…

Results of Operations and Financial Condition. On March 12, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by reference into, this Item…

Other Events On February 11, 2026, the Company issued a press release announcing it received FDA clearance of an IND for its PBGENE-DMD program for treatment of DMD. The FDA Study May Proceed notification enables initiation of clinical trial site activities for the FUNCTION-DMD Phase1/2 clinical trial. The Company has the goal of activating the first clinical site in the U.S. in the first half of 2026. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K c…

and this Item 7.01 (including the Press Release attached hereto as Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any registration statement or other filing of the Company under the Securities Act of 1933, as amended, or the Ex…

Other Events On January 12, 2026, the Company announced additional biopsy data in the ELIMINATE-B trial for PBGENE-HBV is expected in the first half of 2026. In addition, the Company expects to complete dosing Cohorts 3, 4, and 5 and choose the optimal dosing regimen to achieve the goal of stopping nucleos(t)ide analog treatment and begin Part 2 expansion of the trial. Pending clearance of the investigational new drug application, the FUNCTION-DMD Phase 1/2 clinical trial in Duchenne muscular…

Results of Operations and Financial Condition. Although it has not finalized its full financial results for the year ended December 31, 2025, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025. This estimate is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025, or its re…

Other Events. On November 10, 2025, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC (the “Underwriter”), in connection with the offering (the “Offering”), issuance and sale by the Company of 10,815,000 shares of its common stock, $0.000005 par value per share (the “Common Stock”) and accompanying one-half warrants to purchase up to 5,407,500 shares of Common Stock at a combined price of $6.14 and…

Other Events On November 10, 2025, the Company issued a press release announcing a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. The presentation includes data from the ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, an in vivo gene editing therapy designed to eliminate cccDNA, the root cause of chronic Hepatitis B, and inactivate integrated HBV DNA. As of the October 31, 2025 data cutoff date, nine evalua…

Results of Operations and Financial Condition. On November 3, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The company amended employment agreements for its Section 16 officers to include new severance and escrow arrangements.

Results of Operations and Financial Condition. On August 7, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Other Events On August 6, 2025, the Company announced Phase 1 safety and efficacy for Cohort 1, the lowest dose level in the ELIMINATE-B clinical trial. Cohort 1 of the Phase 1 ELIMINATE-B study consisted of three patients each of whom received three planned administrations of 0.2 mg/kg of PBGENE-HBV dosed approximately eight weeks apart. The primary objective of the ELIMINATE-B study is to characterize the safety of PBGENE-HBV, and the dose in Cohort 1 was selected to maximize the safety mar…

Results of Operations and Financial Condition. On May 15, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On March 26, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Director: The reclassification of directors' classes and the reduction in board size were administrative changes to maintain balanced director classes.

Director — Sam Wadsworth, Ph.D.: Dr. Sam Wadsworth retired from the Board of Directors.

Results of Operations and Financial Condition. Although it has not finalized its full financial results for the year ended December 31, 2024, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $108.5 million in cash, cash equivalents, and restricted cash as of December 31, 2024 before the receipt of $2.5 million from TG Therapeutics and other cash inflows in January 2025. This estimate is unaudited and preliminary and does not present all information neces…